KCM
ARTL icon

Kathmere Capital Management’s Artelo Biosciences ARTL Stock Holding History

Kathmere Capital Management’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,472
Closed -$100K – 680
2026
Q1 		$100K Buy
+1,472
New +$62.7K 0.01% 607

Other funds holding ARTL

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Danske Bank
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Kathmere Capital Management's ARTL Position: Q2 2026 in Review

Kathmere Capital Management sold out of Artelo Biosciences (ARTL) in Q2 2026, closing a stake of 1,472 shares — an estimated $100K sold.

Kathmere Capital Management first reported a position in ARTL in Q1 2026 and held it in 1 quarter. The position peaked at $100K in Q1 2026. 7 funds tracked by Wall St. Rank hold ARTL as of Q2 2026.

  • Kathmere Capital Management reported no remaining Artelo Biosciences position as of Q2 2026 after selling out during the quarter.
  • Kathmere Capital Management sold 1,472 Artelo Biosciences shares in Q2 2026, an estimated $100K.
  • Kathmere Capital Management first reported a position in Artelo Biosciences in Q1 2026 and held it in 1 quarter.
  • Kathmere Capital Management's Artelo Biosciences position peaked at $100K in Q1 2026.
  • 7 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.